Elimusertib

also known as BAY1895344 · ELIMUSERTIB (BAY-1895344)

Small molecule targets ATR via inhibition

Developed for: gastric carcinoma · metastatic malignant neoplasm · pancreatic adenocarcinoma · small cell lung carcinoma · alveolar rhabdomyosarcoma · bile duct carcinoma · bone cancer · cancer
+30 more
· carcinoma of esophagus · cervical carcinoma · colorectal carcinoma · endometrial carcinoma · Ewing sarcoma · fallopian tube serous adenocarcinoma · female breast carcinoma · gastroesophageal junction adenocarcinoma · head and neck carcinoma · high grade malignant neoplasm · hypopharynx squamous cell carcinoma · intrahepatic bile duct cancer · laryngeal squamous cell carcinoma · lymphoma · major salivary gland carcinoma · malignant pleural mesothelioma · mantle cell lymphoma · non-small cell lung carcinoma · oropharynx squamous cell carcinoma · ovarian cancer · ovarian carcinoma · ovarian serous adenocarcinoma · paranasal sinus squamous cell carcinoma · penile carcinoma · primary peritoneal serous adenocarcinoma · refractory malignant neoplasm · salivary gland squamous cell carcinoma · skin squamous cell carcinoma · triple-negative breast carcinoma · urothelial carcinoma
Investigated by: National Cancer Institute (NCI) · Bayer · GlaxoSmithKline · M.D. Anderson Cancer Center · Merck Sharp & Dohme LLC

Trials 10 · a red edge is where a trial was stopped

today NCT04576091 · Ph 1 NCT05010096 · Ph 1 NCT05071209 · Ph 1/2 NCT04514497 · Ph 1 NCT04491942 · Ph 1 NCT04535401 · Ph 1 NCT04616534 · Ph 1 NCT04267939 · Ph 1 NCT04095273 · Ph 1 NCT03188965 · Ph 1

2018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 19 trials
Phase 1	NCT04576091	Jul 2022 → Nov 2024 overdue	hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, major salivary gland carcinoma, oropharynx squamous cell carcinoma +3	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT05010096	Mar 2022	bone cancer, high grade malignant neoplasm, metastatic malignant neoplasm	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded
Phase 1	NCT04514497	Oct 2021 → Feb 2025 overdue	metastatic malignant neoplasm, pancreatic adenocarcinoma, small cell lung carcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT04491942	Aug 2021 → Jun 2027 expected	bile duct carcinoma, carcinoma of esophagus, cervical carcinoma, endometrial carcinoma +11	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT04535401	Aug 2021 → Feb 2025 overdue	colorectal carcinoma, gastric carcinoma, gastroesophageal junction adenocarcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT04616534	Jun 2021 → Apr 2025 overdue	fallopian tube serous adenocarcinoma, ovarian serous adenocarcinoma, pancreatic adenocarcinoma, primary peritoneal serous adenocarcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT04267939	Feb 2020 → Dec 2023	ovarian cancer	Bayer	Terminated	No outcome recorded
Phase 1	NCT04095273	Sep 2019 → Nov 2022	cancer	Bayer	Completed	No outcome recorded
Phase 1	NCT03188965	Jul 2017 → Dec 2022	mantle cell lymphoma	Bayer	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT05071209	Dec 2021 → Sep 2024 overdue	Ewing sarcoma, alveolar rhabdomyosarcoma, lymphoma, refractory malignant neoplasm	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

Field	Value	Cited text
Known as	Elimusertib	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03188965 ↗ 9 NCT05071209 ↗ NCT04095273 ↗ NCT04514497 ↗ NCT04267939 ↗ NCT04491942 ↗ NCT05010096 ↗ NCT04535401 ↗ NCT04576091 ↗ NCT04616534 ↗
Known as	BAY1895344	“The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with elimusertib (BAY1895344) in combination with pembrolizumab.” NCT04095273 ↗ 2 “Elimusertib (BAY1895344)” NCT04267939 ↗ “Elimusertib (BAY1895344)” NCT03188965 ↗
Known as	ELIMUSERTIB (BAY-1895344)	ChEMBL registry synonym — accepted as the source's own label CHEMBL4647810 ↗
Action	Inhibit	“elimusertib, works by blocking a substance (ATR Kinase)” NCT04095273 ↗
Modality	Small molecule	— CHEMBL4647810 ↗
Route	Oral	“Solution or tablet, oral, to be administered until evidence of tumor progression” NCT03188965 ↗
Target	ATR	“blocking a substance (ATR Kinase)” NCT04095273 ↗